29 January 2015
You'd have to be deaf, dumb and blind to have overlooked the supercharged sense of optimism at JP Morgan a few weeks ago. There's more money pumping into the industry through venture funds, private equity, IPOs and follow-ons than ever before. And today's news that the first trio of U.S. biotech IPOs got off the ground--with one potential breakout in the group--signals that the good times aren't over yet.
What you may have overlooked, though, is that the fever that has been driving new deals in the U.S. has also spread to Europe. Nick Taylor picked up on that with his latest missive from the continent, noting that biotech IPOs in Europe last year raised more than twice what was raised in all the IPOs of the previous 5 years. Biotech venture funding in the U.K. soared 41%, with the golden triangle of London, Cambridge and Oxford commanding the lion's share of the cash.
So where do we go from here? I'll be in London on February 4 to discuss that topic with some of the experts: Anja Koenig, managing director of the Novartis Venture Fund; Kevin Johnson at Index Ventures; Patrick Verheyen, head of J&J's Innovation center in London and David Phillips, a partner at GlaxoSmithKline's SR One.
14 March 2024
26 February 2024
NovaMedica team wishes you a Merry Christmas and a Happy New Year!
26 December 2023
Big Pharma’s ROI for drug R&D saw 'welcome' rebound in 2023: report
25 April 2024
Orphan drug market to reach $270B by 2028 : Evaluate
25 April 2024
Russian drug for the treatment of viral hepatitis will be exempt from duty in Mongolia
24 April 2024
PM Mishustin: “We need to increase the production of vital and essential drugs in Russia”
24 April 2024